Autonomix Medical, Inc. reported its financial results for the third quarter of fiscal year 2025, ended December 31, 2024, on February 13, 2025. The company incurred a net loss of $2.7 million for the quarter, an improvement compared to a net loss of $3.1 million for the same period in 2023.
General and administrative expenses decreased to $1.7 million from $2.2 million in the prior year, primarily due to a decrease in advertising expense, partially offset by increases in compensation and professional fees. Research and development expenses increased to $1.0 million from $0.7 million, driven by clinical trial and product development costs.
As of December 31, 2024, Autonomix had cash and cash equivalents of $11.8 million, an increase from the previous quarter, reflecting recent financing activities. The company confirmed it remains on track to report topline data from its PoC trial in the first half of 2025 and to initiate U.S. clinical trials in 2025, supporting a potential FDA clearance in 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.